Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis

References

• Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
   Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252–262.
   Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
   Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441.
   Google Scholar
• Gasparotto M, Gatto M, and Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v39–v51.
   Google Scholar
• Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: improving global outcomes (KDIGO) consensus conference. Perit Dial Int. 2021;41(1):5–14.
   Google Scholar
• McCloskey O, Maxwell AP. Diagnosis and management of nephrotic syndrome. Practitioner. 2017;261(1801):11–15.
   Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018;93(4):789–796.
   Google Scholar
• Fanouriakis A, Kostopoulou M, and Cheema K, et al. Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2019;79(6):713–723. 2020.
   Google Scholar
• Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305–1313.
   Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779.
   Google Scholar
• KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1–S276.
   Google Scholar
• Anders HJ, Loutan J, Bruchfeld A, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol Dial Transplant. 2021 Dec 9. DOI:10.1093/ndt/gfab351 .
   Google Scholar
• Mok CC, Hamijoyo L, Kasitanon L, et al. The Asia-Pacific league of associations for rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol. 2021;3:e517–31.
   Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128.
   Google Scholar
• Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013;65(6):1586–1591.
   Google Scholar
• Rovin BH, Teng YKO, Ginzler EM, et al., Efficacy and safety of voclosporin versus placebo for lupus nephritis (Aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 397(10289): 2070–2080. 2021.
   Google Scholar
• Mejía-Vilet JM, Ayoub I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med (Lausanne). 2021;8:622225.
   Google Scholar
• Lupkynis, voclosporin [prescribing information] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf.
   Google Scholar
• Benlysta B [prescribing information] 2017 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125370s062lbl.pdf.
   Google Scholar
• Benlysta, belimumab [summary of product characteristics] 2016 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf.
   Google Scholar
• US Food and Drug Administration. Voclosporin Approval Letter, 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000Approv.pdf.
   Google Scholar
• Furie R, Aroca G, and Alvarez A, et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Arthritis Rheumatol. 2020;72(suppl 10). [cited 2022 Jun, 27]. Available from: https://acrabstracts.org/abstract/two-year-results-from-a-randomized-controlled-study-of-obinutuzumab-for-proliferative-lupus-nephritis/. abstract 0988.
   Google Scholar
• Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transplant Int. 2005;18(4):379–384.
   Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
   Google Scholar
• Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity – what the FK? Adv Chronic Kidney Dis. 2020;27(1):56–66.
   Google Scholar
• Roy J, Cyert MS. Identifying new substrates and functions for an old enzyme: calcineurin. Cold Spring Harb Perspect Biol. 2020;12(3):a035436.
   Google Scholar
• Prograf, tacrolimus [prescribing information] 2012 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050709s031lbl.pdf.
   Google Scholar
• Gengraf, cyclosporin. [prescribing information] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.gengraf.com/prescribinginformation.
   Google Scholar
• Li Y, Palmisano M, Sun D, et al. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin Pharmacol. 2020;12:83–96.
   Google Scholar
• Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001–2010.
   Google Scholar
• Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–244.
   Google Scholar
• Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467–1472.
   Google Scholar
• Wang S, Li X, Qu L, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012;21(9):1025–1035.
   Google Scholar
• Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18–26.
   Google Scholar
• Zhou T, Lin S, Yang S, et al. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019;13:857–869.
   Google Scholar
• Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307.
   Google Scholar
• Rovin BH, Solomons N, Pendergraft WF,3, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219–231.
   Google Scholar
• Ponticelli C, Podestà MA. Calcineurin inhibitors in lupus nephritis. J Nephrol. 2021;34:399–402.
   Google Scholar
• Kuglstatter A, Mueller F, Kusznir E, et al. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 2):119–123.
   Google Scholar
• Ling SY, Huizinga RB, Mayo PR, et al. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013;53(12):1303–1312.
   Google Scholar
• US Food and Drug Administration. Multi-disciplinary review and evaluation, NDA 213716 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf.
   Google Scholar
• Ling SY, Huizinga RB, Mayo PR, et al. Cytochrome P450 3A and P-glycoprotein drug–drug interactions with voclosporin. Br J Clin Pharmacol. 2014;77(6):1039–1050.
   Google Scholar
• Wang CP, Burckart GJ, Venkataramanan R, et al. Cyclosporine metabolite profiles in the blood of liver transplant patients. Transplant Proc. 1988;20(1 Suppl 1):173–175.
   Google Scholar
• US National Library of Medicine PubChem 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin.
   Google Scholar
• Wang CP, Burckart GJ, Ptachcinski RJ, et al. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc. 1988;20(2 Suppl 2):591–596.
   Google Scholar
• Kempkes-Koch M, Fobker M, Erren M, et al. Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc. 2001;33(3):2167216–2167219.
   Google Scholar
• Roby KA, Shaw LM. Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol. 1993;4(2):168–177.
   Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al., The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9): 931–938.
   Google Scholar
• Liao R, Liu Q, Zheng Z, et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015;10(7):e0132724.
   Google Scholar
• Mejía-Vilet JM, Romero-Díaz J. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis. Expert Rev Clin Immunol. 2021;17(9):937–945.
   Google Scholar
• Keisuke S, Kohei M, Takuji E, et al. Role of cathepsin L in idiopathic nephrotic syndrome in children. Med Hypotheses. 2020;141:109718.
   Google Scholar
• Mayo PR, Huizinga RB, Ling SY, et al. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013;53(8):819–826.
   Google Scholar
• Bîrsan T, Dambrin C, Freitag DG, et al. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transplant Int. 2005;17(12):767–771.
   Google Scholar
• Stalder M, Bîrsan T, Hubble RW, et al. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003;22(12):1343–1352.
   Google Scholar
• van Gelder T, Huizinga RB, Noukens J, et al. Use of TDM does not add clinical value for voclosporin in patients with lupus nephritis [abstract PO 1918]. J Am Soc Nephrol. 2020;31(Kidney Week 2020):594.
   Google Scholar
• Quien RM, Kaiser BA, Dunn SP, et al. Calcineurin activity in children with renal transplants receiving cyclosporine. Transplantation. 1997;64(10):1486–1489.
   Google Scholar
• Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther. 1999;21(10):1632–1652.
   Google Scholar
• Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(1):35–41.
   Google Scholar
• Hošková L, Málek I, Kopkan L, et al. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res. 2017;66(2):167–180.
   Google Scholar
• Gregoor PJ, de S??vaux RG, Hen?? RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68(10):1603–1606.
   Google Scholar
• van Gelder T. How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. Kidney Int. 2021;100(6):1185–1189.
   Google Scholar
• van Gelder T, Huizinga RB, Lisk L, et al. Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. Nephrol Dial Transplant. 2022 Apr 25;37(5):917-922. DOI: 10.1093/ndt/gfab022.
   Google Scholar
• Ponticelli C, Reggiani F, and Moroni G. Old and new calcineurin inhibitors in lupus nephritis. J Clin Med. 2021;10:4832.
   Google Scholar
• Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484–1493.
   Google Scholar
• Askanase A, Randhawa S, Lisk L, et al. Efficacy of voclosporin across lupus nephritis biopsy classes: pooled data from the Aurora and AURA-LV trials. Presented at the virtual Nation Kidney Foundation 2021 Spring Clinical Meeting, 2021 Apr 6–10. Poster 283 [cited 2022 Mar 15]. https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/abstracts?abstractId=1878
   Google Scholar
• US National Library of Medicine ClinicalTrials.gov [Internet] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https://clinicaltrials.gov/ct2/show/NCT03597464.
   Google Scholar
• Saxena A, Mela C, Coeshall A, editors. Voclosporin for lupus nephritis: interim analysis of the Aurora 2 extension study [abstract 1425]. American College of Rheumatology Convergence; 2021. cited 2022 Mar 15]. Available from 2022 Mar 15 https://acrabstracts.org/abstract/voclosporin-for-lupus-nephritis-interim-analysis-of-the-aurora-2-extension-study/
   Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–1112.
   Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379.
   Google Scholar
• Pochineni V, Rondon-Berrios H. Electrolyte and acid–base disorders in the renal transplant recipient. Front Med (Lausanne). 2018 Oct 2; 5:261
   Google Scholar
• Lee CH, Kim GH. Electrolyte and acid-base disturbances induced by calcineurin inhibitors. Electrolyte Blood Press. 2007;5(2):126–130.
   Google Scholar
• De Waele L, Van Gaal PJ, Abramowicz D. Electrolytes disturbances after kidney transplantation. Acta Clin Belg. 2019;74(1):48–52.
   Google Scholar
• Tumlin JA, Rovin BH, and Rahman M, et al. Voclosporin therapy in active lupus nephritis: reduced hypertension and electrolyte complications with CNI treatment [abstract]. 2017th ed. Vol.32, European renal association-European dialysis and transplant association Madrid Spain: Nephrology Dialysis Transplantation; 2017.
   Google Scholar
• Kolic J, Beet L, Overby P, et al. Differential effects of voclosporin and tacrolimus on insulin secretion from human islets. Endocrinology. 2020;161(11):bqaa162.
   Google Scholar
• Busque S, Cantarovich M, Mulgaonkar S, et al., The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 11(12): 2675–2684. 2011.
   Google Scholar
• Otsuka press release 2021. [cited 2022 Mar 15]. Available from: https://www.otsuka.co.jp/en/company/newsreleases/2021/20210625_1.html.
   Google Scholar
• Takeuchi T, Wakasugi N, Uno S, et al. Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST). J Rheumatol. 2021;48:74–81.
   Google Scholar
• Tice JA, Mandrik O, Thokala P, et al. The effectiveness and value of belimumab and voclosporin for lupus nephritis. J Manag Care Spec Pharm. 2021;27(10):1495–1499.
   Google Scholar